Is it time to cash in on Sigma shares?

Shares have extended after the Chemist Warehouse merger.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

For those who've owned Sigma Healthcare Ltd (ASX: SIG) shares this year, it's been a joyful ride.

Shares in the ASX healthcare stock are up more than 148% this year to date on the back of the planned merger with Chemist Warehouse.

Sigma shares surged nearly 40% shortly after the Australian Competition and Consumer Commission (ACCC) approved the deal.

But with such a rally comes significant profits for those holding large stakes in the company.

According to ASX filings this week, HMC Capital Ltd (ASX: HMC) has completed a large sell-down in its Sigma position.

This raises the question of whether now is a prime opportunity to cash in. Let's take a closer look.

Two lab workers fist pump each other.

Image source: Getty Images

Why is HMC Capital offloading Sigma shares?

The Sigma–Chemist Warehouse deal was approved on 7 November after a lengthy review process that examined potential anti-competition impacts.

Completed via a backdoor listing, the deal saw the pair merge to create a healthcare giant that, according to the ACCC, was "unlikely to substantially lessen competition".

Sigma shares exploded higher on the news. And while plenty of investors were buying for the near-term gains, some shareholders were downsizing their positions.

HMC Capital immediately sold down its stake in Sigma, dropping its holdings from 10.64% to 8.24% on the same day as the ACCC's decision.

The asset manager's reduction in Sigma shares has been ongoing, starting back in April when it sold approximately 4% of its holdings.

HMC initially bought into Sigma at around 70 cents per share in 2022, according to The Australian, making its recent sales an exit at a solid profit.

The financial services company isn't exiting Sigma completely, however. It is just reducing its holdings.

Still, brokers are cautious about what's next. According to CommSec, consensus rates the stock a 'moderate' sell.

This comprises three sell ratings, four holds, and one broker still advising to buy Sigma shares.

Where is HMC Capital now investing?

Where or how HMC will use the funds generated from the sell-downs isn't clear. But elsewhere, the company is channelling its resources into the digital infrastructure space.

In a separate update, the company announced it acquired the iSeek data centre platform in Australia for $400 million. It marks the foundation of its planned DigiCo digital infrastructure platform.

The acquisition, alongside others, could form the basis of a future ASX-listed property trust:

These acquisitions will seed an ASX-listed DigiCo Infrastructure REIT (DigiCo REIT)
2 with [over $4 billion] of [assets under management] AUM…

… Once it is established, it is proposed that DigiCo REIT will be a stapled entity consisting of a company and a registered managed investment scheme. Shares in the company will be stapled to units in the managed investment scheme on a one for one basis to form stapled securities.

Foolish takeaway

Sigma shares are in the limelight after the ACCC approved its merger with Chemist Warehouse this month.

Where to from here is a matter of economic debate, but also the fundamentals of both companies.

Sigma shares are up more than 267% in the past year.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Female in elegant outfit smiling and gesturing victory with hands.
Healthcare Shares

Are Telix shares a buy after flying 40% higher in March?

Telix shares are up another 5.3% on Tuesday.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces.
Healthcare Shares

Down 30% today, is it time to buy into this beaten-down biotech share?

While there's been bad news, this company has more irons in the fire.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

What's the impact of US tariffs on Aussie drugmakers CSL and Mayne Pharma?

Is the US' bark worse than its bite?

Read more »

Health professional working on his laptop.
Healthcare Shares

Mesoblast shares are back in the red on Tuesday. Here's why

Mesoblast shares slip despite another strong quarterly sales update from Ryoncil.

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Earnings Results

Why are Telix shares jumping 8% today?

The radiopharmaceuticals company's shares are starting the week strongly.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Mesoblast shares: Ryoncil® underpins strong earnings growth

Mesoblast shares are in focus as Ryoncil® delivers nearly US$100m in sales since launch, fueling future growth initiatives.

Read more »

medical asx share price represented by doctor giving thumbs up
Healthcare Shares

Telix Pharmaceuticals Q1 2026: Revenue growth, guidance reaffirmed

Telix Pharmaceuticals lifts Q1 revenue 11%, reports pipeline progress, and keeps its full-year guidance on track.

Read more »

Five healthcare workers standing together and smiling.
Healthcare Shares

3 ASX 200 healthcare shares to buy amid sector rout

The experts are backing these stocks for price growth.

Read more »